The global heterozygous familial hypercholesterolemia (HEFH) market might, by 2033, amount to US$58.54 billion. From US$13.2 billion in 2022, the sum has grown dramatically, demonstrating a 14.5% compound annual growth rate (CAGR).
Hypercholesterolemia (HEFH) is a hereditary condition characterized by excessive levels of low-density lipoprotein (LDL) cholesterol, also known as “bad cholesterol.” This buildup of cholesterol can obstruct blood flow and significantly increase the risk of stroke and heart attack.
One of the main factors propelling the growth of this form of hypercholesterolemia’s market is the rise in the prevalence of the condition brought on by an increase in the number of people living unhealthy lifestyles that result in obesity. The aging population, the frequency of cardiovascular disease, and several other chronic conditions like diabetes, kidney issues, and thyroid issues all raise the risk of hypercholesterolemia. The market’s revenue is also raised by these elements. The launch of new drugs, increased research, and technical developments in the treatment of hypercholesterolemia are the main factors driving the market’s revenue growth.
Refine Strategies: Request Your Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16343
However, the primary obstacles impeding the market’s capacity to grow in terms of revenue are the high cost of current Managements, a number of risk concerns associated with the drugs used to treat hypercholesterolemia, and a lack of diagnostic tools for the ailment. During the forecast period, a number of government initiatives aimed at increasing public awareness of the signs, causes, and available treatments for hypercholesterolemia, technological advancements in the treatment of the condition, improved healthcare facilities, an increase in research and drug development for the condition, and higher healthcare spending are anticipated to generate profitable growth opportunities. These advancements should encourage growth..
Key Takeaways from the Market Study
- The global HEFH management market is currently worth more than US$ 13 Billion.
- In 2023, the ST-103 segment by product type is expected to take the dominant market share of 32%.
- Hospitals to account for over 1/5th of all HEFH management procedures as of 2023
- North America is expected to exhibit CAGR of 15.3% from 2023-2033, with regard to HEFH management
- The European market for HEFH management is expected to grow with a steady CAGR of 14% from 2023-2033
“The improvement of healthcare infrastructure, government initiatives to raise public awareness of the causes, symptoms, and treatments for hypercholesterolemia, improved research and drug development for the treatment, as well as increased healthcare investments will all contribute to the growth of the heterozygous familial hypercholesterolemia management market during the forecast period.” comments a Future Market Insights analyst.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16343
Competitive Landscape
Some of the top players in the global market are Sanofi SA, Amgen Inc., Novartis International AG, AdooQ Bioscience, Thermo Fisher Scientific, Universal Biologicals, Selleck Chemicals, Madrigal Pharmaceuticals, ShangHai Caerulum Pharma Discovery Co., Ltd. and Wuhan Biocar Pharmacy. Some recent developments in this domain are:
- NewAmsterdam Pharma, a clinical-stage business focusing on the discovery and development of transformational oral treatments for metabolic illnesses, said today that it has begun a Phase 2 dose-finding trial of obicetrapib as an addition to stable statin therapy among Japanese patients with dyslipidemia with BROOKLYN in 2022. In addition to maximally tolerated lipid-lowering treatment, the BROOKLYN Phase 3 study examines the impact of obicetrapib on LDL-C levels in individuals with heterozygous familial hypercholesterolemia.
More Valuable Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market, presenting historical demand data (2018-2022) and forecast statistics from 2023 to 2033.
The study divulges essential insights on the market based on the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market by product type (Gemcabene Calcium, MGL-3196, ST-103, Others), by application (hospitals, medical centers and clinics) and regions.
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
Key Segments Covered in the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Report
By Product Type:
- Gemcabene Calcium
- MGL-3196
- ST-103
- Others
By Application:
- Hospitals
- Medical Centers
- Clinics
- Others
Explore In-Depth Market Research: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16343
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
